Rhumatotogie. Les coxibes augmentent-ils les risques cardiovasculaires [Rheumatology. Do coxibs pose a cardiovascular risk?]

Détails

ID Serval
serval:BIB_3A5ADC39C93C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Rhumatotogie. Les coxibes augmentent-ils les risques cardiovasculaires [Rheumatology. Do coxibs pose a cardiovascular risk?]
Périodique
Revue Médicale Suisse
Auteur⸱e⸱s
So A., de Goumoëns P.
ISSN
1660-9379
Statut éditorial
Publié
Date de publication
2005
Volume
1
Numéro
2
Pages
168-172
Langue
français
Résumé
There is ongoing controversy regarding the cardiovascular safety of coxibes. Inhibition of COX-2 may have a pro-coagulant effect though available data does not support a class effect in human use. In clinical practice, prudence with its prescription is recommended. In cases which require treatment beyond one week, the individual cardiovascular and gastrointestinal risks need to be assessed. If the risk is predominantly gastrointestinal, a COXIB is indicated. If the cardiovascular risk is major, then a classical NSAID with gastric protection may be more appropriate.
Mots-clé
Cardiovascular Diseases, Cyclooxygenase Inhibitors, Humans, Risk Factors
Pubmed
Création de la notice
02/03/2009 14:24
Dernière modification de la notice
20/08/2019 13:30
Données d'usage